BofA lowered the firm’s price target on Doximity (DOCS) to $56 from $70 and keeps a Buy rating on the shares. While the company is investing in technology and spending to scale its AI product, which will put pressure on EBITDA margins in the neart-erm while the company also deals with more limited visibility, the firm sees “a couple reasons to be optimistic,” the analyst tells investors in a post-earnings note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target lowered to $37 from $62 at Truist
- Doximity price target lowered to $34 from $46 at Goldman Sachs
- Doximity price target lowered to $49 from $65 at Morgan Stanley
- Doximity price target lowered to $30 from $55 at Evercore ISI
- Doximity price target lowered to $25 from $45 at BMO Capital